ArticleFrontiers in immunology2026
Molecular sensitization profiles and β-parvalbumin sensitization burden associated with clinical fish allergy in children.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fish allergy is a potentially severe condition that is frequently managed with broad elimination diets. Molecular allergology may improve risk stratification by distinguishing clinically relevant fish allergy from asymptomatic sensitization. We aimed to characterize molecular sensitization patterns in fish-sensitized children and identify molecular profiles associated with clinical fish allergy. Methods: Sixty-one fish-sensitized children (0-18 years) were evaluated using a multiplex molecular allergy assay (ALEX2). Twenty-eight children were classified as fish-allergic based on a positive oral food challenge (OFC) or consistent clinical reactions, whereas 33 sensitized children were clinically tolerant. Molecular sensitization patterns were analyzed using Bayesian logistic model averaging (BMA), Firth penalized logistic regression, receiver operating characteristic (ROC) analysis, and hierarchical clustering. Results: Sensitization to β-parvalbumins was significantly more frequent in allergic than tolerant children. Allergic children also exhibited a substantially higher cumulative β-parvalbumin sensitization burden (median 7 [IQR 5-7] vs 3 [IQR 1-5]; p<0.001). BMA prioritized Clu h 1, Gad m 2_3, and Cyp c 1 as the molecular allergens most strongly associated with clinical fish allergy. Sensitization to Gad m 2_3 was observed exclusively among allergic children. An exploratory parsimonious model incorporating cumulative β-parvalbumin sensitization burden together with Gad m 2_3 achieved an optimism-corrected AUC of 0.867. Conclusions: Molecular sensitization profiles, particularly the cumulative burden of β-parvalbumin sensitization, were associated with clinical fish allergy in children. Clu h 1 and Cyp c 1 emerged as the molecular markers most consistently associated with clinical reactivity, whereas Gad m 2_3 was observed only among allergic children in this cohort and may represent a low-prevalence exploratory finding. These findings suggest a potential role for molecular allergen profiling in risk stratification among fish-sensitized children but require validation in larger independent cohorts before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.